|
answer text |
<p>The Managed Access Agreement for nusinersen for the treatment of spinal muscular
atrophy which has been approved by NHS England, Biogen, the National Institute for
Health and Care Excellence, the three main patient groups (Muscular Dystrophy UK,
Spinal Muscular Atrophy UK, Treat SMA) and clinicians can be found at the following
link:</p><p><a href="https://www.nice.org.uk/guidance/gid-ta10281/documents/committee-papers-2"
target="_blank">https://www.nice.org.uk/guidance/gid-ta10281/documents/committee-papers-2</a></p>
|
|